Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

<p>Celltrion's management continues to make very optimistic projections about Remsima's US sales in 2017 despite regulatory hurdles that will limit the drug's initial acceptance. We think that the stock ultimately will be a significant disappointment as reality collides with hope. Newcomers to this story should review the Insight Stream for background information and context.</p>

Celltrion's management continues to make very optimistic projections about Remsima's US sales in 2017 despite regulatory hurdles that will limit the drug's initial acceptance. We think that the stock ultimately will be a significant disappointment as reality collides with hope. Newcomers to this story should review the Insight Stream for background information and context.

Celltrion Inc

One World, Two Stories